Last reviewed · How we verify

LiNing — Portfolio Competitive Intelligence Brief

LiNing pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
oxaliplatin plus capecitabine oxaliplatin plus capecitabine marketed Platinum-based chemotherapy combination DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU) Oncology
docetaxel plus oxaliplatin and capecitabine docetaxel plus oxaliplatin and capecitabine phase 3 chemotherapeutic agents Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for LiNing:

Cite this brief

Drug Landscape (2026). LiNing — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lining. Accessed 2026-05-14.

Related